Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

Literature DB >> 25469210

The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

Claudia V Andreu-Vieyra¹, James R Berenson².

Abstract

Panobinostat is an investigational and potent histone deacetylase inhibitor (HDACi) that has shown promise as an antimultiple myeloma agent in the preclinical setting. In this review, we discuss the rationale for the use of panobinostat as a combination therapy for multiple myeloma and provide an overview of recent and ongoing clinical trials testing the safety and efficacy of panobinostat for the treatment of the disease.

Entities: Chemical Disease Species

Keywords: histone deacetylase inhibitor; multiple myeloma; panobinostat

Year: 2014 PMID： 25469210 PMCID： PMC4250267 DOI： 10.1177/2040620714552614

Source DB: PubMed Journal: Ther Adv Hematol ISSN： 2040-6207

66 in total

1. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

Authors: Sridurga Mithraprabhu; Tiffany Khong; Simon S Jones; Andrew Spencer
Journal: Br J Haematol Date: 2013-05-21 Impact factor: 6.998

2. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

Authors: Ruben Niesvizky; Scott Ely; Tomer Mark; Sangeeta Aggarwal; Janice L Gabrilove; John J Wright; Selina Chen-Kiang; Joseph A Sparano
Journal: Cancer Date: 2010-09-22 Impact factor: 6.860

3. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors: Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal: Blood Date: 2013-08-15 Impact factor: 22.113

4. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Authors: Patricia Maiso; Xonia Carvajal-Vergara; Enrique M Ocio; Ricardo López-Pérez; Gema Mateo; Norma Gutiérrez; Peter Atadja; Atanasio Pandiella; Jesús F San Miguel
Journal: Cancer Res Date: 2006-06-01 Impact factor: 12.701

5. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

Authors: Richard A Campbell; Eric Sanchez; Jeffrey Steinberg; Dror Shalitin; Zhi-Wei Li; Haiming Chen; James R Berenson
Journal: Eur J Haematol Date: 2009-11-18 Impact factor: 2.997

6. Recent improvement in survival of patients with multiple myeloma: variation by ethnicity.

Authors: Dianne Pulte; Maria Theresa Redaniel; Hermann Brenner; Lina Jansen; Mona Jeffreys
Journal: Leuk Lymphoma Date: 2013-09-03

7. Measurement of instant rates of protein degradation in the livers of intact mice by the accumulation of bestatin-induced peptides.

Authors: V Botbol; O A Scornik
Journal: J Biol Chem Date: 1991-02-05 Impact factor: 5.157

Review 8. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.

Authors: Robert Z Orlowski
Journal: Semin Oncol Date: 2013-10 Impact factor: 4.929

Review 9. DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Authors: Lauren I Aronson; Faith E Davies
Journal: Haematologica Date: 2012-05-11 Impact factor: 9.941

10. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.

Authors: G M Matthews; M Lefebure; M A Doyle; J Shortt; J Ellul; M Chesi; K M Banks; E Vidacs; D Faulkner; P Atadja; P L Bergsagel; R W Johnstone
Journal: Cell Death Dis Date: 2013-09-12 Impact factor: 8.469

14 in total

1. Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.

Authors: Donald Moore
Journal: P T Date: 2016-05

2. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.

Authors: Anthony Wood; Saby George; Nabil Adra; Sreenivasulu Chintala; Nur Damayanti; Roberto Pili
Journal: Invest New Drugs Date: 2019-10-25 Impact factor: 3.850

3. Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.

Authors: Kevin B Daniel; Eric D Sullivan; Yao Chen; Joshua C Chan; Patricia A Jennings; Carol A Fierke; Seth M Cohen
Journal: J Med Chem Date: 2015-06-02 Impact factor: 7.446

Review 4. Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.

Authors: Meng-Ge Yu; Hu-Yong Zheng
Journal: Chin Med J (Engl) Date: 2017-01-20 Impact factor: 2.628

5. Epigenetic Activation of Pro-angiogenic Signaling Pathways in Human Endothelial Progenitors Increases Vasculogenesis.

Authors: Sylvain Fraineau; Carmen G Palii; Brian McNeill; Morten Ritso; William C Shelley; Nutan Prasain; Alphonse Chu; Elodie Vion; Kristy Rieck; Sharmin Nilufar; Theodore J Perkins; Michael A Rudnicki; David S Allan; Mervin C Yoder; Erik J Suuronen; Marjorie Brand
Journal: Stem Cell Reports Date: 2017-10-12 Impact factor: 7.765

6. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.

Authors: Joana N R Dias; Sandra I Aguiar; Diane M Pereira; Ana S André; Lurdes Gano; João D G Correia; Belmira Carrapiço; Barbara Rütgen; Rui Malhó; Conceição Peleteiro; João Goncalves; Cecília M P Rodrigues; Solange Gil; Luís Tavares; Frederico Aires-da-Silva
Journal: Oncotarget Date: 2018-06-19

7. Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.

Authors: Song Mu; Yoshiaki Kuroda; Hirohiko Shibayama; Masayuki Hino; Takeshi Tajima; Claudia Corrado; Rong Lin; Edward Waldron; Florence Binlich; Kenshi Suzuki
Journal: Eur J Clin Pharmacol Date: 2015-10-22 Impact factor: 2.953